VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in Roivant Sciences Ltd. $ROIV

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 61,200 shares of the company’s stock, valued at approximately $2,166,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in Roivant Sciences by 4,212.2% during the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock worth $672,448,000 after buying an additional 18,560,434 shares during the period. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Norges Bank purchased a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $112,750,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $76,272,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055,913 shares of company stock valued at $107,261,258 over the last three months. 8.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on ROIV. Citigroup raised their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen upped their target price on Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Jefferies Financial Group lifted their price target on Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.62.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant reported positive Phase 2 results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a reported 56.3% placebo-adjusted reduction in pulmonary vascular resistance, and Roivant has begun the Phase 3 PHrontier trial. The results strengthen the case for a potentially important new therapy and were the primary reason for the recent rally. Roivant Reports Positive Mosliciguat Phase 2 Results
• Positive Sentiment: Jefferies raised its price target for ROIV to $52 from its prior target, while H.C. Wainwright increased its target to $47. The revisions signal continued analyst confidence following the mosliciguat data. Jefferies Raises Roivant Price Target H.C. Wainwright Raises Roivant Price Target
• Positive Sentiment: Large call-option activity and reports that hedge-fund ownership rose 41% in the second quarter indicate strong investor interest and bullish positioning, although options activity can also increase volatility. Roivant Call Option Activity
• Neutral Sentiment: Roivant presented at Citigroup’s Biopharma Back to School Summit and the Cantor Fitzgerald Global Healthcare Conference. These events may provide additional pipeline commentary, but the available reports do not identify a new material announcement. Citigroup Summit Transcript
• Negative Sentiment: The stock’s retreat appears to reflect profit-taking after reaching a record high near $42.50, rather than a clearly negative company-specific announcement. Roivant remains loss-making, and its valuation leaves the shares sensitive to clinical-trial execution and future regulatory risk.

Roivant Sciences Price Performance

Shares of ROIV opened at $40.94 on Friday. Roivant Sciences Ltd. has a 1-year low of $13.81 and a 1-year high of $42.50. The stock has a market cap of $29.57 billion, a price-to-earnings ratio of -77.25 and a beta of 1.12. The firm has a 50 day simple moving average of $35.68 and a 200-day simple moving average of $31.56.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. On average, equities analysts expect that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.